In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Annie Chou Annie Chou is a writer covering home office, cameras, and games.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results